Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer
Breast Cancer
DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: 5-fluorouracil|DRUG: Docetaxel
Disease free survival, 5 year
distant metastasis free survival, 5 year|event free survival, 5 year|overall survival, 5 year
This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer